Show simple item record

dc.contributor.authorLockbaum, Gordon J.
dc.contributor.authorHenes, Mina
dc.contributor.authorLee, Jeong Min.
dc.contributor.authorTimm, Jennifer
dc.contributor.authorNalivaika, Ellen A.
dc.contributor.authorThompson, Paul R
dc.contributor.authorYilmaz, Nese Kurt
dc.contributor.authorSchiffer, Celia A.
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:20Z
dc.date.available2022-08-23T15:45:20Z
dc.date.issued2021-10-05
dc.date.submitted2021-09-30
dc.identifier.citation<p>Lockbaum GJ, Henes M, Lee JM, Timm J, Nalivaika EA, Thompson PR, Kurt Yilmaz N, Schiffer CA. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode. Biochemistry. 2021 Oct 5;60(39):2925-2931. doi: 10.1021/acs.biochem.1c00414. Epub 2021 Sep 10. PMID: 34506130; PMCID: PMC8457326. <a href="https://doi.org/10.1021/acs.biochem.1c00414">Link to article on publisher's site</a></p>
dc.identifier.issn0006-2960 (Linking)
dc.identifier.doi10.1021/acs.biochem.1c00414
dc.identifier.pmid34506130
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27503
dc.description.abstractRupintrivir targets the 3C cysteine proteases of the picornaviridae family, which includes rhinoviruses and enteroviruses that cause a range of human diseases. Despite being a pan-3C protease inhibitor, rupintrivir activity is extremely weak against the homologous 3C-like protease of SARS-CoV-2. In this study, the crystal structures of rupintrivir were determined bound to enterovirus 68 (EV68) 3C protease and the 3C-like main protease (M(pro)) from SARS-CoV-2. While the EV68 3C protease-rupintrivir structure was similar to previously determined complexes with other picornavirus 3C proteases, rupintrivir bound in a unique conformation to the active site of SARS-CoV-2 M(pro) splitting the catalytic cysteine and histidine residues. This bifurcation of the catalytic dyad may provide a novel approach for inhibiting cysteine proteases.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=34506130&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457326/
dc.subjectrupintrivir
dc.subject3C cysteine proteases
dc.subjectpan-3C protease inhibitor
dc.subjectSARS-CoV-2
dc.subjectBiochemistry
dc.subjectChemistry
dc.subjectEnzymes and Coenzymes
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectStructural Biology
dc.subjectVirus Diseases
dc.subjectViruses
dc.titlePan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode
dc.typeJournal Article
dc.source.journaltitleBiochemistry
dc.source.volume60
dc.source.issue39
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/303
dc.identifier.contextkey25210840
html.description.abstract<p>Rupintrivir targets the 3C cysteine proteases of the picornaviridae family, which includes rhinoviruses and enteroviruses that cause a range of human diseases. Despite being a pan-3C protease inhibitor, rupintrivir activity is extremely weak against the homologous 3C-like protease of SARS-CoV-2. In this study, the crystal structures of rupintrivir were determined bound to enterovirus 68 (EV68) 3C protease and the 3C-like main protease (M(pro)) from SARS-CoV-2. While the EV68 3C protease-rupintrivir structure was similar to previously determined complexes with other picornavirus 3C proteases, rupintrivir bound in a unique conformation to the active site of SARS-CoV-2 M(pro) splitting the catalytic cysteine and histidine residues. This bifurcation of the catalytic dyad may provide a novel approach for inhibiting cysteine proteases.</p>
dc.identifier.submissionpathcovid19/303
dc.contributor.departmentThompson Lab
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages2925-2931


This item appears in the following Collection(s)

Show simple item record